

October 2, 2018

To: ANS/AOS Members

From: Kristen Bordignon, ANS/AOS Administrator

Hi all,

ANS/AOS receives multiple requests for mass e-mailings and Surveys and Questionnaires to the membership. We realize that our membership has unique expertise which can further our societal objectives of professional education and advancement of neurotology, however the number of requests for email lists and distribution of surveys was growing. The ANS Executive Council wished to provide our membership access to all the possible information that they would like without having multiple e-mail become an ineffective tool.

In 2014, ANS introduced a biannual email "blast" to the membership to include announcements, invitations to participate in studies and email surveys of interest to the society. The emails will be sent in May and October annually. Starting in 2018, the Executive Council has asked the ANS Research Committee Chairperson to preview the content of such surveys/questionnaires to be sure the content is appropriate for members and related to the ANS mission. Although you may not find every announcement or survey relevant to you, those who took the time to prepare the surveys would appreciate your consideration and participation. We have four surveys, a "seeking patients" announcement and COSM CFP info.

Please have your requests for inclusion of surveys or membership queries in this group email sent to all ANS members to Kristen Bordignon, the ANS Administrator, by April 17 or September 17 for inclusion in the subsequent email "blast."

With that said, here is the 2nd "biannual" email of 2018. Please take a moment to open the attached pdf, you will find a wealth of information relevant to the Societies as far as COSM meeting information, CFP, abstract deadline, research funds, etc... You can access all the links within the pdf. I will post this on the ANS website under News & Resources - Reference Links as well.

For those of you pre-registered for "Super Saturday", October 6, 2018 in Atlanta, an email with meeting information, badge pick-up, logistics, and other pertinent information will be emailed to you tomorrow, Wednesday, October 3rd.

Thanks,
Kristen

MARK YOUR CALENDAR! - DEADLINE OCTOBER 15!

**CALL FOR PAPERS
AMERICAN NEUROTOLOGY SOCIETY**

JW Marriott Austin
Austin, TX
May 3-5, 2019

**ABSTRACTS ACCEPTED until Monday, October 15, 2018
MIDNIGHT PT**

AWARDS AVAILABLE

NICHOLAS TOROK VESTIBULAR AWARD (\$1500)
TRAINEE AWARD (\$1000)
NEUROTOLOGY FELLOW AWARD (\$500)

(*Abstract must be selected as an ORAL presentation to be considered for the above awards)

Please visit the ANS website for further information & detailed submission instructions
<https://www.americanneurologysociety.com/ans-abstract-form-submission-page-2019>

CALL FOR PAPERS
AMERICAN OTOLOGICAL SOCIETY
The 152nd Annual Spring Meeting
JW Marriott Austin
Austin, TX
May 3-5, 2019

ABSTRACTS ACCEPTED until Monday, October 15, 2018
MIDNIGHT PT

AWARDS AVAILABLE
RESIDENT RESEARCH TRAVEL AWARD* (2)

for

Outstanding Clinical or Basic Science Manuscripts

Deadline line for Submission: October 15, 2018

(*Abstract must be selected as an ORAL presentation to be considered for this award)

A complete manuscript is required before 12/3/18)

CASH AWARD FOR BEST PRESENTATION FROM RESEARCH PERFORMED IN A PRIVATE PRACTICE SETTING

(*Abstract must be selected as an ORAL presentation to be considered for this award;

the recipient must be primary author/presenter)

Deadline line for Submission: October 15, 2018

Please see website for further information and online submission instructions.

<https://www.americanotologicalsociety.org/aos-abstract-form-submission-page-2019>

LOOKING FOR RESEARCH FUNDS?

AMERICAN OTOLOGICAL SOCIETY RESEARCH FUND

RESEARCH GRANT AWARDS AND TRAINING FELLOWSHIPS

SAVE THE DATE - NOVEMBER 1, 2018

A letter of intent must be submitted by November 1st of the year *prior* to funding (the next funding cycle begins July 1, 2019). The letter must state the grant mechanism for the proposal, the Principal Investigator and Institution(s) for the work, provide a working title, and abstract. This should contain the Specific Aims and summarize the proposal in no more than 2 pages.

Complete applications will be invited from selected applicants based on our review of the letters of intent. Applicants will be notified by December 1st whether they have been chosen to submit a full application. Complete applications must be received by January 31st.

You may direct specific questions to John S. Oghalai, MD, Executive Secretary, Research Fund of the American Otological Society, Inc. Email: john.oghalai@med.usc.edu or assistant to Dr. Oghalai, Kristen Bordignon.

E-mail: administrator@americanotologicalsociety.org

Complete instructions are available on AOS website, check here for the answer to many of your questions.

<http://www.americanotologicalsociety.org/aos-grant-submission-instructions>

ANS RESEARCH GRANT APPLICATION DUE - MARCH 1, 2019

[Click here for details of the ANS research grant!](#)

SURVEYS

Dear Colleagues,

We are asking that you complete a brief survey consisting of 15 questions that should take no more than 5 minutes to complete. We aim to assess trends in treatment and rates of vaccination in the management of patients with cerebrospinal fluid leakage by Otolaryngologists and Neurosurgeons.

Please click on the link below to complete the REDCap research survey:

<https://octri.ohsu.edu/redcap/surveys/?s=DLNNDKJWTT>

Completion of this survey is completely voluntary; however, your responses are highly valued and will provide important insights. Thank you for your time and participation.

Sincerely,

Timothy E. Hullar, MD

Professor

Department of Otolaryngology – Head and Neck Surgery

Oregon Health and Science University

Email: hullar@ohsu.edu

Member ANS/AOS

Dear Colleagues,

We invite you to participate in a survey being conducted through Emory University. *The purpose of this study is to learn if and how healthcare providers who **regularly see persons with hearing loss** assess for **cognitive impairment**.* The survey will take less than **three minutes**. We will not collect any identifying information about you. Participation is completely voluntary and there is little risk of breach of confidentiality. IRB approval was obtained and any questions should be forwarded to mjraymo@emory.edu or to the Emory Institutional Review Board at 404-712-0720 or by email at irb@emory.edu. By clicking the link below, you signify your consent to participate in the study.

https://docs.google.com/forms/d/e/1FAIpQLSfB2Dgna72p0LW-RR9kNN20n_jr0CfGgowncsC9Gyq2SBzRiA/viewform?usp=sf_link

Thank you very much for your time and participation.

Sincerely,

Mallory Raymond MD PGY-4

Department of Otolaryngology - Head and Neck Surgery

Emory University Hospital

mjraymo@emory.edu | 561-707-8940

ANS Member affiliation: Esther X. Vivas, MD

Dear Members,

Superior Semicircular Canal Dehiscence (SSCD) was first described by Minor et al. in 1992. Since its initial description, there have been numerous articles written about this disorder. Despite the knowledge about this problem, there is controversy regarding diagnosis, presentation, and management arising partially from the myriad symptoms that can be attributed to both SSCD and other otologic/neurotologic disorders. Despite the wide array of symptoms that are classically described in SSCD, the prevalence of symptoms lacks a clear pattern. Some patients with confirmed SSCD on radiological imaging present with only one symptom in isolation, such as disabling aural fullness, or a lack of symptoms altogether.

Given the plethora of symptoms and the range of noninvasive options (balance rehabilitation) to invasive options (middle cranial fossa resurfacing and plugging of the SSC) for management, it appears that many of us may offer different options for our patients. Thus, this survey is attempting to glean from the membership some of the details and nuances of the strategies for helping patients with SSCD.

Survey Link:

https://survey.az1.qualtrics.com/jfe/form/SV_ctZkftzWHGHtMb3

Thank you so much!

Ashley Cozart

UCF College of Medicine, Class of 2021

ANS/AOS member affiliation: Michael D. Seidman, MD

Dear Provider,

Despite recent guidelines published in both otolaryngology and neurology literature, debate still exists regarding the appropriate approach to acute, non-traumatic facial palsy. Antivirals, imaging, and routine laboratory blood-work are some of the areas in which various clinicians differ in their initial approach.

We aim to identify and delineate differences in the management of acute facial palsy in a non-traumatic setting both among different specialties (otolaryngology, neurology, pediatrics, etc.) as well as within individual specialties.

Your participation is voluntary. All answers provided, and identities of participants are anonymous.

Attached is a survey on the management of acute, non-traumatic facial nerve palsy. It contains 5-10 questions and should take less 5 minutes. We would greatly appreciate your input.

Here is the survey link: https://yalesurvey.ca1.qualtrics.com/jfe/form/SV_bJae5xNxM9xE8Tj

If you have any questions about the survey or about our study, please feel free to contact Dr. Douglas Hildrew at douglas.hildrew@yale.edu or Dr. David Kasle at david.kasle@yale.edu.

Thank you in advance for your time,

David Kasle, MD

Sina J. Torabi, BA

ANS member affiliation: Douglas M. Hildrew, MD

SEEKING PATIENTS!

(no affiliation with the American Neurotology Society)

Does Aspirin Help in the Treatment of Sporadic or NF-2 Related Vestibular Schwannoma?

PI: Konstantina Stankovic, MD, PhD ([Konstantina Stankovic@meei.harvard.edu](mailto:Konstantina_Stankovic@meei.harvard.edu)) and D. Bradley Welling, MD, PhD ([Brad Welling@meei.harvard.edu](mailto:Brad_Welling@meei.harvard.edu))

This is a phase 2 trial of aspirin in the treatment of vestibular schwannoma. In a previous retrospective study of 347 vestibular schwannoma patients seen at Mass Eye and Ear, the probability of tumor growth in patients who took aspirin for unrelated medical reasons was *about half* that of patients who did not take aspirin. However, that trend was not observed in retrospective studies from other institutions. In the current study, we are looking to prospectively enroll 300 vestibular schwannoma patients at 6 centers nationally, including Mass Eye and Ear, Mass General Hospital, Mayo Clinic, University of Utah, University of Iowa, and Stanford University.

The aim of the study is to definitely determine whether aspirin can prevent or halt progression of vestibular schwannoma. We are enrolling patients aged 12 and up that have been diagnosed within the past 2 years OR have growing tumors (at least 2mm growth in one dimension in a year). Patients with sporadic and NF2-associated vestibular schwannomas can enroll. Enrolled patients are randomized 1:1 to 325 mg oral aspirin twice daily or placebo twice daily (pediatric patients weighing less than 50 kg and randomized to receive drug will be given 81 mg oral aspirin twice daily). If you have newly diagnosed patients (within 2 years) or patients with growing tumors, please contact Edina Shu ([Edina Shu@meei.harvard.edu](mailto:Edina_Shu@meei.harvard.edu)) to refer your patients.

MISCELLANEOUS ANNOUNCEMENTS

AAO-HNSF Announces Otolaryngology United for Global Patient Care Initiative

The AAO-HNSF is spearheading a medical supplies and instrument donation drive in conjunction with the AAO-HNSF 2018 Annual Meeting & OTO Experience. This humanitarian effort, which runs from now through December 31, 2018, is being done in collaboration with MedShare, a 501c(3) humanitarian aid organization headquartered in Atlanta, Georgia. MedShare is dedicated to improving the “quality of life of people, communities and our planet” by sourcing and directly delivering surplus medical supplies and equipment to communities in need around the world.

If you wish to donate supplies, representatives from MedShare will be onsite at the Annual AAO-HNSF Meeting in the OTO Experience on October 7-9, 2018.

Click here for [Program Details](#)

Warm regards,
Mark E. Zafereo, MD
AAO-HNSF Humanitarian Efforts Committee Chair

MARK YOUR CALENDAR!

COSM 2019 registration will open Monday, January 28, 2019. Housing Reservations at the JW MARRIOT AUSTIN, 110 E 2nd St, Austin, TX are being accepted NOW on [COSM website!](#)

ANS DIVERSITY & INCLUSION COMMITTEE IS HARD AT WORK!

STAY TUNED! The ANS DIVERSITY & INCLUSION COMMITTEE will be sending an electronic survey regarding member engagement and perception of issues related to diversity and inclusion. This will be sent to all members after the Fall meeting. **UNDER CONSTRUCTION!** Look for the DIVERSITY/INCLUSION TAB on the ANS website, you will find a newsletter next week, <https://www.americanneurotologysociety.com/diversity-inclusion>

This concludes the biannual email, I hope you take the time to respond to the surveys. All surveys have been reviewed by the ANS Research Committee Chair, Dr. Ronna Hertzano, for relevance to the ANS mission before they are accepted for distribution. Thank you Ronna!

Please have your requests for inclusion of surveys, membership queries or announcements in this group email sent to all ANS/AOS members to Kristen Bordignon, by April 17, 2019 for inclusion in the May email “blast”. (next email will go out AFTER COSM). This document will be available on the ANS Website under “Reference Links” and “Announcements”.